iVeena Delivery Systems Inc. announced key executive promotions designed to strengthen operational leadership and advance its scientific vision. Effective immediately, Michael Burr, MBA, MS, has been promoted to COO, and Sarah Molokhia, RPh, PhD, has been promoted to chief scientific officer (CSO). Long-time company COO Ned Weinshenker, PhD, is moving into the role of vice president of chemistry, manufacturing, & controls (CMC).

These promotions reflect iVeena’s commitment to scaling its organizational capabilities and accelerating development of its lead asset, IVMED-85, a first-in-class investigational eye drop for pediatric myopia. The timing of the promotions coincides with the anticipated initiation of a phase 1 study in healthy adult volunteers.

In his new role as COO, Burr will oversee company-wide operations, driving strategic execution across development programs, corporate initiatives, and cross-functional activities. With more than 15 years of experience in ocular drug delivery and device development, he previously served as vice president of product development at iVeena, where he led product strategy for pipeline assets.

Dr. Molokhia steps into the role of CSO with responsibility for shaping the company’s scientific strategy, research priorities, and clinical translation activities. As former vice president of research & development, she has spearheaded critical research in ocular drug delivery, including IND-enabling work for IVMED-85 and securing competitive grant funding to support preclinical progress in myopia control.